Kornimate/medical-research-clean huggingface dataset:
online cognitive behavioural therapy intervention for body dysmorphic disorder

Conditions: Body Dysmorphic Disorder; Body Image Disturbance

Summary: body dysmorphic disorder (bdd) affects 2.3% of the population and is characterized by excessive concerns with imagined or minor defects in physical appearance. retrospective outcome studies suggest patients affected by bdd don't typically benefit from surgical treatments while cognitive behaviour therapy (cbt) appears to provide symptom - reducing and distress - reducing benefits. two different 8-week online cbt approaches to assisting individuals with this disorder are compared: one approach will integrate mindfulness meditation methods (in combination with cbt) and one approach will employ cbt methods without reference to mindfulness meditation.

body dysmorphic disorder (bdd) affects 2.3% of the population and is characterized by excessive concerns with imagined or minor defects in physical appearance. retrospective outcome studies suggest patients affected by bdd typically do not benefit from surgical treatments while cognitive behaviour therapy (cbt) appears to provide symptom - reducing and distress - reducing benefits. in this study two different 8-week online cbt approaches to assist individuals with this disorder are compared: one approach will integrate mindfulness meditation methods (in combination with cbt) and one approach will employ cbt methods without reference to mindfulness meditation. the purpose of this comparison is to ascertain whether the inclusions of the two additional intervention modalities, demonstrated effective in other studies, adds to positive outcome effects in this disorder. a primary hypothesis is that the 8 week post-intervention outcomes associated with the cbt-mindfulness approach will show significantly more benefit than the comparison group.

Eligibility criteria:
inclusion criteria: on the body dysmorphic disorder questionnaire, responses indicating current bdd status; - exclusion criteria: individuals who are currently receiving weekly structured psychotherapy or who meet dsm-v criteria for severe alcohol/substance use disorder in the past 3 months or demonstrated clinically significant suicidal ideation defined as imminent intent, or attempted suicide in the past 6 months. individuals of co-morbid diagnoses of borderline personality, schizophrenia, bipolar disorder and/or obsessive compulsive disorder are excluded. -

Keywords: internet-based intervention with health coaching
specified drug use-results survey (long-term use) on minirinmelt® od tablet (nocturia)

Conditions: Nocturia Due to Nocturnal Polyuria

Summary: to investigate the incidence and risk factors of desmopressin-induced hyponatremia during long-term treatment (1 year \[52 weeks\]) of minirinmelt orally disintegrating (od) tablets 25μg/50μg (drug) for nocturia caused by nocturnal polyuria in men in daily clinical practice, and to confirm the compliance with proper use of this drug in clinical practice and to investigate the effectiveness of risk minimization activities.


Eligibility criteria:
inclusion criteria: * participants who received the minirinmelt for the first time in men with nocturia due to nocturnal polyuria, an indication for drug. exclusion criteria: * no exclusion criteria defined for this study.

Keywords: hyponatremia long-term treatment
efficacy and safety of nvp-1203 and nvp-1203-r in patients with acute low back pain

Conditions: Acute Low Back Pain

Summary: the purpose of this study is to evaluate the efficacy and safety nvp-1203 in patients with acute low back pain.

this study is a randomized, double-blind, active-controlled, parallel, phase 3 study to evaluate efficacy and safety of nvp-1203 in patients with acute low back pain.

Eligibility criteria:
inclusion criteria: * subjects who have ability to comprehend the contents of study and before participating in trial and have willingness to sign of informed consent in writing * subjects who have symptom of acute low back pain exclusion criteria: * subjects who cannot prohibit anti-inflammatory drug or muscle relaxants during clinical trial * inadequate subject for the clinical trial by the investigator's decision
endocrine glucose & lipids metabolism and brain aging: a longitudinal study

Conditions: Brain Aging Related Conditions

Summary: with aging, brain aging leads to a general decline in cognitive ability, and the prevalence of neurodegenerative diseases such as alzheimer's disease (ad) and parkinson's disease (pd) increases. the prevalence of abnormal glucose and lipid metabolism also increased with age. the imbalance of glucose and lipid metabolism is closely related to brain aging related conditions and diseases, and the relationship between glucose and lipid metabolism and brain aging has not been fully elucidated. phase 1: baseline investigation (community-based survey) aims: to investigate whether glucose and lipids are the risk factors for brain aging-related conditions, such as mild cognitive impairment. subjects and methods: a community-based survey will be carried out in 10000 natural population aged \>=50 years selected from 10-12 communities stratified according to geographic regions (ciyao, huafeng, dongzhuang, heshan, geshi, jiangji, gangcheng, fushan, dongshu, sidian, baxianqiao, and xiangyin, etc) in ningyang county, taian city, shandong province. a comprehensive examination including questionnaire (including the mmse and adl evaluation for the participants), anthropometric measurements, biochemical analysis will be performed in each study participant. in particular, the investigators randomly selected 1000-2000 participants performing mri of the brain to evaluate the brain aging related conditions. phase 2: cohort follow-up aims : to examine glucose and lipids metabolism levels and their changes that modify the risk of brain aging-related conditions. subjects and methods: to recruit and follow all 10000 participants for at least 3-5 years. in particular, all 1000-2000 participants with the baseline mri examination will perform the mri examination again for the follow-up.


Eligibility criteria:
inclusion criteria: 1. age \>= 50 years old; 2. gender: males and females; 3. provide written informed consent; 4. satisfactory compliance. exclusion criteria: 1. pregnant or lactating women 2. no history of addiction or neurological, psychiatric, or systemic diseases known to affect cognitive function, including head trauma, subdural hematoma, current depression, and epilepsy 3. any other condition or major systemic diseases that the investigator feels would interfere with trial participation or evaluation of results.

Keywords: brain aging cognition lipid glucose
the effect of shelf nutrition labels on purchases

Conditions: Obesity

Summary: nuval® shelf nutrition labels rate the nutritional quality of foods on a scale of 1 (worst) to 100 (best). in 2014, nuval updated their nutrient profiling system which changed the nuval score on many foods. the investigators took advantage of this "natural experiment" to assess the extent to which a change in the nuval score at a grocery chain influenced yogurt purchases, a category with a wide range of more and less healthy alternatives. the investigators supplemented the retail scanner data with a survey of consumers in stores using nuval labels to obtain their experience with the labels and the extent to which they state it influences their purchases.


Eligibility criteria:
inclusion criteria: * us adults regularly shopping at one of two retail chains using nuval exclusion criteria: -

Keywords: shelf nutrition label, nuval
the effect of andrographis paniculata (ap) on palliative management of advanced esophageal cancer

Conditions: Squamous Cell Carcinoma of Esophagus

Summary: this is a prospective cohort study on the effect of andrographis paniculata (ap) on palliative management of patients with advanced or metastatic esophageal cancer. a total of 30 patients with locally advanced or metastatic squamous esophageal cancer will be recruited for the trial.


Eligibility criteria:
inclusion criteria: 1. aged over 18 2. locally advanced esophageal cancer with invasion or adherent to surrounding organs including trachea, recurrent laryngeal nerves and descending aorta; 3. presence of distant metastasis; 4. extensive lymph node metastasis to beyond surgical therapy exclusion criteria: 1. patients who cannot receive palliative stenting for dysphagia or under other conventional treatment including chemotherapy or chemoradiotherapy 2. patients who are not willing to receive chinese herbal medicines 3. patients who do not consent for the study
is augmentation of porh by rosuvastatin adenosine-receptor mediated?

Conditions: Atherosclerosis; Cardiovascular Disease

Summary: rationale: statins form a class of drugs that is widely prescribed for hypercholesterolaemia, specifically to reduce the risk on atherosclerosis by lowering ldl-cholesterol. next to the effect for which the drug was originally developed, it became obvious that statins have several other beneficial effects. such pleiotropic effects include the activation of ecto-5'-nucleotidase which can increase endogenous adenosine production (by dephosphorylation adenosine monophosphate into adenosine) and subsequently cause vasodilation. a recent study of meijer et al (not yet published) showed that rosuvastatin significantly augments vasodilation after a brief period of ischemia (post occlusive reactive hyperaemia). however, it is not yet verified whether this increase in post occlusive reactive hyperaemia is truly caused by a rise of extracellular adenosine and subsequent adenosine receptor stimulation. in this study, the mechanism by which rosuvastatin augments post occlusive reactive hyperaemia will be investigated by blocking adenosine receptors with caffeine, a competitive a1 and a2 adenosine receptor antagonist. caffeine is a substance that can be safely used in normal concentrations to block the adenosine receptor. hypothesis: the augmenting effect of rosuvastatin on porh is caused by an increase of extracellular adenosine formation and this effect can be diminished by blocking the adenosine receptor using caffeine. objective: to study the influence of caffeine on post occlusive reactive hyperaemia before and after 7 days treatment with rosuvastatin. study design: open label cross-over design study population: healthy volunteers, 18-50 years of age intervention: eight volunteers will receive a 7 day treatment with rosuvastatin 20 mg daily before and after rosuvastatin treatment caffeine will be administrated intra-arterially. main study parameters/endpoints: forearm blood flow (fbf) will be measured as an indicator for post occlusive reactive hyperaemia (porh).


Eligibility criteria:
inclusion criteria: * age 18-50 * written informed consent exclusion criteria: * history of any cardiovascular disease * hypertension (in supine position: systole \>140 mmhg, diastole \>90 mmhg) * diabetes mellitus (fasting glucose \>7.0 mmol/l or random glucose \>11.0 mmol/l) * hyperlipidemia (fasting total cholesterol \>5.5 mmol/l or random cholesterol \>6.5 mmol/l) * alanine amino transferase \>90 u/l * creatin kinase \>440 u/l * raised rhabdomyolysis risk (gfr \<80 ml/min and/or overt clinical signs of hypothyroidism and/or myopathy in family history * alcohol abuse * concommitant chronic use of medication * participation to any drug-investigation during the previous 60 days as checked with vip check
comparison of constraint-induced movement therapy and bimanual intensive therapy through tele-rehabilitation for cp

Conditions: Cerebral Palsy

Summary: cerebral palsy is a neurological condition affecting movement and posture, caused by non-progressive brain disruptions occurring during fetal development. constraint-induced movement therapy (cimt) significantly improves arm and hand function in children with hemiparetic cerebral palsy by using intensive therapy sessions and restricting the unaffected limb to develop new motor skills. bimanual therapy involves using both hands repeatedly to perform functional tasks, rather than relying on just one hand. tele-rehabilitation (tr) is an affordable method of providing remote rehabilitation services through telecommunication technologies like smartphones and media applications. the aim of the study is to compare the effectiveness of cimt and bimanual therapy delivered via tele-rehabilitation for improving upper limb function in children with cerebral palsy. this randomized clinical trial will be conducted at mubarik medical complex, sargodha, pakistan, with a sample size of 65. participants will be randomly allocated into two groups using an online randomization tool, group a will receive constraint-induced movement therapy (cimt) intervention for 60 minutes, and group b will receive bimanual therapy intervention for 60 minutes. each participant will undergo treatment for three days a week on alternate days for eight weeks. spasticity will be assessed by using the modified ashworth scale. the quality of upper extremity skills test (quest) will evaluate dissociated movement, grasp, protective extension, and weight bearing, while the tele-rehabilitation satisfaction survey (tess) is designed to evaluate the experiences and satisfaction levels of patients or caregivers who have participated in tele-rehabilitation programs. measurements will be taken at baseline, 4th week, 8th week, and at 12th week after discontinuation of treatment. the data will be entered and assessed using spss 26. for between-group analysis of parametric data, the independent t-test will be used, while non-parametric data will be analyzed using the mann-whitney test. within-group comparisons will be conducted using repeated measures anova for parametric data and friedman anova for non-parametric data.


Eligibility criteria:
inclusion criteria: * age 6-12 years. * children with hemiplegic cerebral palsy with mild to moderate hand involvement. * ability to extend wrist \&gt;20° and fingers at the metacarpophalangeal joints \&gt;10° from full flexion * demonstrated ability to follow instructions during screening and complete the testing. * spasticity does not exceed a score of 1 or 1+ on the modified ashworth scale exclusion criteria: * health problems unassociated with cp. * visual problems interfering with treatment. * active or unstable seizures. * orthopedic surgery on the more affected hand within the last year.

Keywords: cerebral palsy neurological disorder physiotherapy techniques movement disorder muscle spasticity
a study to evaluate the safety and efficacy of sitagliptin 100 mg in participants with type 2 diabetes mellitus who have inadequate glycemic control (mk-0431-229)

Conditions: Type 2 Diabetes Mellitus

Summary: this study will evaluate whether the addition of sitagliptin treatment provides a greater decrease in a1c levels compared to placebo in participants with inadequate glycemic control on sulfonylurea and metformin combination therapy.


Eligibility criteria:
inclusion criteria: * type 2 diabetes mellitus * hemoglobin a1c of ≥7.5% and ≤10.5% * currently taking a stable dose of metformin (at least 1500 mg/day) and either glimepiride (at least 2 mg/day) or gliclazide (at least 50% of maximum registered dose) for at least 10 weeks prior to study start * male, or a female who is highly unlikely to conceive exclusion criteria: * type 1 diabetes mellitus or ketoacidosis * taking a dipeptidyl peptidase-4 (dpp-4) inhibitor (such as sitagliptin) or a glucagon-like peptide-1 (glp-1) mimetic (such as exenatide or liraglutide) or required insulin therapy within 12 weeks prior to study start * on a weight loss program not in the maintenance phase or on a weight loss medication * history of liver disease, heart failure, heart disease, stroke, high blood pressure, blood disorders, or cancer * hiv positive * pregnant

Keywords: type 2 diabetes mellitus
effect of sinufoam-dexamethasone mixture on post endoscopic sinus surgery outcomes

Conditions: Chronic Rhinosinusitis

Summary: dexamethasone added to sinufoam, which is placed in the ethmoid cavity at the completion of endoscopic sinus surgery, will improve sinonasal mucosal healing.

sinufoam is an fda approved mixture, which is placed in the ethmoid cavity at the completion of an endoscopic sinus surgery procedure. sinufoam prevents scarring and promotes healing of the sinonasal mucosa. sinufoam is commonly mixed with saline, which enables it to be liquefied and gently placed into the ethmoid cavity. recent practice of adding dexamethasone to the sinufoam mixture has been hypothesized to promote healing by reducing chronic inflammation associated with crs. using topical dexamethasone mixed into the sinufoam solution may improve patient care by preventing the systemic effects associated with post-operative systemic steroid use.

Eligibility criteria:
inclusion criteria: * age \>18 years old * chronic rhinosinusitis without nasal polyps --- defined according to the aao guidelines * elective "bilateral" sinus surgery requiring at a minimum of an uncinectomy, maxillary antrostomy, and anterior ethmoidectomy. exclusion criteria: * uncorrectable coagulopathy * emergency procedure * unavailable for standard post operative follow-up * sinonasal neoplasm resections * excessive intra-operative bleeding requiring nasal packing

Keywords: chronic rhinosinusitis endoscopic sinus surgery sinufoam dexamethasone for patients with chronic rhinosinusitis without nasal polyps focus: define the postoperative sinonasal mucosal healing status of 2 sinufoam mixtures
liver biomarkers in anorexia nervosa

Conditions: Anorexia Nervosa

Summary: the main goal of the liver biomarkers in anorexia nervosa (liban) study is to determine the prevalence of liver fibrosis in patient with anorexia nervosa.

prevalence of hepatic fibrosis will be non-invasively investigated, in the anorexia nervosa inpatient population, using the fibroscan ®. furthermore, liver blood markers will be assessed.

Eligibility criteria:
inclusion criteria : * patient over 15 years old * diagnosis of restricted eating disorders including anorexia nervosa according to the diagnostic and statistical manual of mental disorders (dsm-5) * admission to the endocrinology, diabetology and nutrition department of the nantes university hospital. exclusion criteria : * chronic active viral hepatitis * hemochromatosis * other genetic, autoimmune, toxic or drug-induced hepatitis * treatment with a drug known to induce fatty liver disease (amiodarone, carbamazepine, tamoxifen, valproate, clozapine, anti-retrovirals) unless the dose has been stable for ≥ 3 months * excessive alcohol consumption (≥ 30 grams per day in men, ≥ 20 grams per day in women)

Keywords: liver fibrosis liver steatosis enteral refeeding anorexia nervosa
study the safety and efficacy of bone marrow derived autologous cells for the treatment of spinal cord injury

Conditions: Spinal Cord Injury.

Summary: this study is a single arm,phase i/ii , single centre trial to check active comparing the safety and efficacy of bone marrow derived autologous cell(100 million per dose) trial to be conducted for 36 months.

a spinal cord injury (sci) refers to any injury to the spinal cord that is caused by trauma instead of disease.\[1\] depending on where the spinal cord and nerve roots are damaged, the symptoms can vary widely, from pain to paralysis to incontinence.\[2\]\[3\] spinal cord injuries are described at various levels of "incomplete", which can vary from having no effect on the patient to a "complete" injury which means a total loss of function.injuries at any level can cause:increased muscle tone (spasticity),loss of normal bowel and bladder control (may include constipation, incontinence, bladder spasms),numbness,sensory changes pain,weakness, paralysis. this study is a single arm,phase i/ii , single centre trial to check active comparing the safety and efficacy of bone marrow derived autologous cell(100 million per dose) trial to be conducted for 36 months.

Eligibility criteria:
inclusion criteria: * patient should suffer from spinal cord injury. * willingness to undergo bone marrow derived autologous cell therapy. * patient those provide fully informed consent form for the study. * ability and willingness to regular visit to hospital and follow up during the protocol procedures. * traumatic injury of spinal cord with complete or partial damage by mri and spinal cord injury level should be below c4 exclusion criteria: * patient with pre- existing or current systemic disease such as lung, liver,(exception:history of uncomplicated hepatitis a)gastrointestinal,cardiac , immunodeficiency(hiv) * history of life threatening allergic or immune - mediated reaction. * haemodynamically unstable patients. * patient suffer from peripheral muscular dystrophy. * lactating and pregnant woman * alcohol drug abuse /dependence * positive test result for hepatitis a and hepatitis b or c * major-traumatic brain injury and patient with psychiatric illness .

Keywords: spinal cord injury stem cell
osseodensification versus motor-driven expanders' techniques for increasing bone density with simultaneous implant placement

Conditions: Alveolar Bone Loss

Summary: the aim of this study was to compare and measure the amount of bone density and ridge width gained with motor driven expanders and densifying burs with simultaneous dental implant placement.

seven patients were treated by the osseodensification technique and another seven were treated by the motor-driven expanders' technique with simultaneous implant placement.

Eligibility criteria:
inclusion criteria: * patients requiring implant placement in the anterior maxilla until the premolar region. * patients are medically fit. * the width of the deficient maxillary alveolar ridge not less than 3mm. * patients willing and fully capable to comply with the study protocol. exclusion criteria: * atrophic ridge (2 mm or less) with no interposition of cancellous bone between the buccal and palatal plates. * uncontrolled metabolic disease (e.g. uncontrolled diabetes). * heavy smokers (\>15 cigarettes/day). * acute oral infections. * untreated periodontal disease. * poor oral hygiene. * pregnant or breastfeeding patient. * a history of radiotherapy to the head and neck region or treatment with bisphosphonates. * female patients using oral contraceptive pills. * presence of oral parafunctional habits. * surgical site needs to be grafted.

Keywords: endosseous implants osseodensification
12-week open-label extension study of tnx-102 sl in ptsd patients

Conditions: PTSD

Summary: this is an open-label, extension trial designed to evaluate safety over 12 additional weeks of tnx-102 sl therapy taken daily at bedtime for the treatment of ptsd. patients recruited into this trial are those who have successfully completed the double-blind lead-in study.

the study will consist of 5 study visits, including screening/baseline visit 1 (day 0, which is anticipated to be the same visit as the last visit on double-blind treatment), a phone visit after 2 weeks of treatment, and in-clinic visits after 4, 8, and 12 weeks of treatment. the primary objective of the study is to evaluate the safety of tnx-102 sl tablets taken daily at bedtime over an additional 12 weeks in patients with ptsd who have completed a double-blinded lead-in study. the secondary objective of the study is to evaluate the efficacy of tnx-102 sl tablets taken daily at bedtime over an additional 12 weeks in patients with ptsd who have completed a double-blinded lead-in study.

Eligibility criteria:
inclusion criteria: * the patient has completed the final treatment study visit of the lead-in study and remained compliant with the lead-in protocol and study treatment. * the patient has provided written informed consent to participate in this extension protocol. * female patients of childbearing potential continue to agree to practice one of the medically acceptable methods of birth control detailed in the lead-in study. exclusion criteria: * none.

Keywords: tnx-102 sl bedtime sublingual 3-month safety efficacy ptsd